youtube_live
Inkomsten Q2 2026 • over 3 dagen
Details tonenchevron_right
GRF:BME
Grifols
€ 9,66
arrow_upward
+2,70%(+0,25) 1D
24 jul, 17:42:30 GMT+2 · EUR
search
Alle symbolen
1D
5D
1M
6M
YTD
1J
5J
MAX
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor GRF genereren…
Openen
€ 9,50
Hoog
€ 9,66
Laag
€ 9,38
Beursw.
5,53 mld.
Gem. vol.
1,78 mln.
Volume
1,89 mln.
Dividend
2,41%
Kwartaaldividend
€ 0,06
Ex-dividenddatum
30 jun 2026
Koers/winst-verhouding
14,34
52 wk hoog
€ 13,70
52 wk laag
€ 8,43
WPA
€ 0,67
Uitstaande aandelen
426,13 mln.
Aantal medewerkers
25K
Openen
€ 9,50
Hoog
€ 9,66
Laag
€ 9,38
Beursw.
5,53 mld.
Gem. vol.
1,78 mln.
Volume
1,89 mln.
Dividend
2,41%
Kwartaaldividend
€ 0,06
Ex-dividenddatum
30 jun 2026
Koers/winst-verhouding
14,34
52 wk hoog
€ 13,70
52 wk laag
€ 8,43
WPA
€ 0,67
Uitstaande aandelen
426,13 mln.
Aantal medewerkers
25K
Nieuwsartikelen
Van bronnen op internet
TradingView
·
19 uur geleden
Grifols SA expected to post earnings of 24 cents a share - Earnings Preview
Profiel
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
Over Grifols
AI-content kan fouten bevatten. Meer informatie